New infusion drug AION-301 aims to slow kidney disease progression

NCT ID NCT06721143

Recruiting now Disease control Sponsor: AION Healthspan, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tests a new drug called AION-301 in 36 adults with Stage 3 chronic kidney disease. Participants receive two infusions of the drug or a placebo, plus vitamins, and are monitored for up to 24 months. The goal is to see if the drug is safe and can reduce symptoms or slow kidney damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

SouthCoast Research Center, Inc.
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Miami, Leonard M. Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE STAGE 3